Replies to post #148938 on Biotech Values

[Summer2762]

I think due to PFS results and crossovers, the market wrongly assumes that the burden of proof lies with the naysayers. Dont forget that the PFS results in an open label P2 study should be discounted slightly and the # of crossovers should not cancel nearly all the OS benefits.